Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms, animal models, and three small pilot human studies.
PubMed 40789979 · doi:10.1007/s12178-025-09990-7
What was done
The authors conducted a narrative scoping review evaluating the molecular mechanisms, therapeutic potential, and safety data for Body Protective Compound-157 (BPC-157) in musculoskeletal healing across preclinical and available clinical literature.
What was found
Preclinical studies indicate that BPC-157 promotes angiogenesis, fibroblast activity, and neuromuscular stabilization through VEGFR2 activation, the Akt-eNOS pathway, and ERK1/2 signaling, particularly in tendons and myotendinous junctions. Human clinical data are limited to three pilot studies addressing intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics; no adverse events were reported, but no quantitative effect sizes or numerical values are reported in the abstract.
Why it matters
Despite widespread off-label use and popularity in sports medicine, BPC-157 remains unproven in humans, and this review clarifies the gap between preclinical promise and clinical reality.
Limits
Evidence is almost entirely preclinical (animal and mechanistic models). Human evidence is limited to three small pilot studies lacking large-scale randomized confirmation. The abstract provides no quantitative data, search protocol details, or total study counts.
Cited by
- supports There is a lack of good quality human clinical evidence demonstrating the efficacy of BPC-157 for injury repair.
- context In 2024, the FDA placed BPC-157 and other peptides onto the Category 2 bulk drug substances list, restricting compounding of these substances.
- supports Numerous animal studies on peptide BPC-157 demonstrate accelerated cartilage repair, nerve regeneration, and angiogenesis.
- context There are no published animal or human studies or case reports on the effects of BPC-157 in endometriosis or fibroids.
- context A Croatian clinical trial evaluated rectal enemas of BPC-157 at doses up to 80 milligrams in patients with ulcerative colitis, finding no adverse events in phase 1 and absence of systemic drug levels in the blood.